SCHEMBL6076892

SCHEMBL6076892

COC(=O)/C(O)=C/C(=O)N(Cc1ccc(F)c(Br)c1)OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
KDM4E B2RXH2 3/20 0.34
FAAH O00519 1/20 0.34
MEP1B Q16820 3/20 0.33
EGFR P00533 1/20 0.33
ALDH1A1 P00352 3/20 0.33
TSHR P16473 2/20 0.33
LMNA P02545 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.32
BMP1 P13497 1/20 0.32
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6076896 1.00 NPSR1 (0.40) NPSR1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6879324 0.91 NPSR1 (0.41) NPSR1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6879322 0.91 NPSR1 (0.41) NPSR1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6077524 0.89 RIPK1 (0.40) KDM4EMEP1BALDH1A1MAOAMAOB
SCHEMBL6077521 0.89 RIPK1 (0.40) KDM4EMEP1BALDH1A1MAOAMAOB
SCHEMBL6984991 0.87 NPSR1 (0.42) NPSR1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6984988 0.87 NPSR1 (0.42) NPSR1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6077237 0.87 MMP13 (0.37) CYP1A2
SCHEMBL6077233 0.87 MMP13 (0.37) CYP1A2
SCHEMBL6413074 0.87 NPSR1 (0.41) NPSR1CYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF NPSR1 4603/4885CYP1A2 483/4885CYP2D6 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.